Investigators used gene panel sequence data to look at rare de novo variant frequencies in potential risk genes for neurodevelopmental disorders with epilepsy.
The number of US states legalizing cannabis for medical and recreational use is growing, expanding the market for pathogen detection solutions.
Going forward, the company will focus on its wholly owned subsidiary Medicinal Genomics Corporation, which conducts cannabis genetics research.
The SBIR Phase 1 award will go toward developing a test using immuno-PCR technology to detect toxins in medical marijuana.
The two firms are collaborating on a system to share genotypic, phenotypic, and treatment outcomes data with physicians on a mobile-device network.
Courtagen will use its ZiPhyr bioinformatics pipeline to help Astellas develop a predictive model that can be used in early-stage drug development.
The life sciences company can now offer its genetic tests in all 50 states in the US, as well as Canada and several other countries.
Proceeds from the financing will be used "to expand our ability to deliver leading-edge services to our customers," Courtagen's CEO said.
A spokesman for Courtagen, which develops NGS-based tests for ailments such as mitochondrial disorders, the $7.5 million is part of a financing round expected to bring in about $17 million.
The deals are with Pronto Diagnostics, headquartered in Tel Aviv, Israel and Medica Labs, based in Bangkok, Thailand.
The American Prospect writes that the pilot program to test the DNA of migrants could lead to more family separations.
An international commission is to develop a report on how researchers, clinicians, and regulators should evaluate the clinical applications of human germline genome editing.
The US Department of Agriculture presents a new blueprint for animal genomic research.
In Genome Research this week: repetitive element deletion linked to altered methylation and more in form of muscular dystrophy; human contamination in draft bacterial and archaeal genomes; and more.